Latest News- Irritable Bowel Syndrome Market: IBS-D is expected to lead the Type segment during 2024-2028

The Irritable Bowel Syndrome Market is being driven by Increasing prevalence of IBS

The Irritable Bowel Syndrome Market is expected to grow at a CAGR of 9.3% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 1931.9 million. The global Irritable Bowel Syndrome (IBS) market is experiencing a significant trend with an increasing number of drug approvals aimed at managing the condition. Regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have expedited the approval process for innovative therapies designed to alleviate IBS symptoms, reflecting the growing recognition of the condition's substantial impact on patients' quality of life and the urgent need for effective treatment options. Notably, in June 2023, Ironwood Pharmaceuticals announced the FDA's approval of a new indication for Linzess (linaclotide) for treating functional constipation in pediatric patients aged 6 to 17 years, further expanding the market landscape. 

Get more information on Irritable Bowel Syndrome Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Type
  • IBS-D
  • IBS-C
  • IBS-M
• Drug Class
  • Antibiotics
  • Guanylate cyclase-C agonists
  • Mu-opioid receptor agonists
  • Chloride channel activators
  • Others
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
  • Asia
    • China
    • India
    • Japan
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Increasing prevalence of IBS
• Growing awareness and diagnosis of IBS
• Rising global healthcare expenditure

However, the market also witnesses some limitations, which are as follows:

• Side effects associated with existing medications
• Increasing number of product recalls
• Prevalence of counterfeit drugs

Benefits of Buying Global Irritable Bowel Syndrome Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Irritable Bowel Syndrome Market Research Report

Request Free Sample

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal discomfort, bloating, gas, cramping, and irregular bowel habits. Sedentary lifestyles and poor eating habits are major contributors to its prevalence. Awareness programs and research funding are essential to increase understanding and advance IBS treatment solutions. Personalized therapeutics, advanced medications, and drug development are key areas of focus. IBS types include IBS-D, IBS-C, and IBS-M, each requiring specific medications such as laxatives, antidiarrheal, antispasmodics, antidepressants, and biologics. Diagnosis campaigns and lifestyle changes, including dietary modifications, are also crucial for effective IBS management.

Market Research Overview

The Irritable Bowel Syndrome (IBS) market is a significant segment of the global pharmaceuticals industry, encompassing entities involved in the research and development (R&D) or production of various types of drugs, including generic and non-generic, as well as veterinary drugs. According to Technavio, the healthcare market size is determined by the consolidated revenue generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. The expansion of the global pharmaceuticals market will be fueled by several factors, including the rise in sedentary lifestyles and poor eating habits leading to an increase in IBS cases. To address this growing health concern, companies are investing in the development of IBS treatment solutions and awareness programs. Advanced medications, therapeutic drugs, and personalized therapeutics are some of the emerging trends in the market. The need for accessible and effective treatment options is driving the drug development process, ensuring continuous innovation and improvement in the IBS treatment landscape.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/